Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Necitumumab plus Gemcitabine-Carboplatin in Squamous NSCLC
NCT02941601Phase 2Withdrawn
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2016
- Primary completion
- Dec 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of necitumumab in squamous cell carcinoma of the lung (SCCL), sponsored by Eli Lilly and Company. Planned start Nov 2016; status: withdrawn.
02
Drugs
necitumumab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT02941601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02941601.